US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Recludix Pharma, Inc.

News headline image
Recludix Pharma to Present at the Oppenheimer Private Life Sciences Company Showcase
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) Congresses
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma to Present at RBC Capital Markets Global Healthcare Conference
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Announces Preclinical Data Demonstrating Efficacy Comparable to Monoclonal Antibodies Targeting IL-4/IL-13 Signaling Pathways and Differentiated Safety Profile of Oral STAT6 Inhibitor REX-8756 (also known as SAR448755) in a Model of Atopic
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and Topical STAT 1/3 Inhibitors at the Society for Investigative Dermatology (SID) Annual Meeting
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Promotes Executive Leaders Following Recent Corporate Accomplishments
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Bolsters Scientific Advisory Board with Acclaimed Leaders in the Fields of Rheumatology, Dermatology and JAK/STAT Biology
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Announces FDA Clearance of Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Enter into the Clinic
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma to Present at Two Investor Conferences in November
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma to Present at the Stifel 2025 Virtual Immunology and Inflammation Forum
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Announces Strengthening of Leadership Team, Including Promotion of Dr. Brian Hodous to Chief Scientific Officer
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Presents Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous Urticaria
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma to Participate in Two Investor Conferences in December
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory Arthritis
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin Inflammation in Oral Plenary Session at SID Annual Meeting
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma to Participate in Two Investor Conferences in March
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma to Present at Two Investor Conferences in February
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma to Present at Two Investor Conferences in November
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Presents Preclinical Data Demonstrating Strong Efficacy and Favorable Safety Profile of REX-7117 Versus TYK2 and JAK Inhibitors at the Dermatology Drug Development Summit
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program at the International Conference of the Inflammation Research Association (IRA)
From Recludix Pharma, Inc.
Via GlobeNewswire